Clinical trials: Vasomotor Symptoms
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Menopause, Hot Flashes
Applied Relaxation for Vasomotor Symptoms
The objectives of this study are to compare frequency and severity of moderate to severe vasomotor symptoms in postmenopausal women treated with applied relaxation (AR) with an untreated control-group (CG) and to investigate if…
- Trial name
- NCT01488864
- Testing
- Applied Relaxation (AR)
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Elizabeth Nedstrand
Menopause
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.
- Trial name
- NCT00962585
- Testing
- S-equol
- Where
- 9 sites in United States, Australia
- Volunteers
- 169 people
- Sponsor
- Ausio Pharmaceuticals, LLC
Aromatherapy
The Effect of Aromatherapy to Women With Vasomotor Complaints on Menopausal Quality of Life and Vasomotor Symptoms
Evaluation of the effect of aromatherapy applied to women with vasomotor complaints on menopausal quality of life and vasomotor symptoms.
- Trial name
- Aromatherapy (NCT06035380)
- Testing
- mint oil group, rose oil group
- Where
- Cyprus
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eastern Mediterranean University
Vasomotor Symptoms
Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms
Breast cancer is the most prevalent cancer type worldwide. In Egypt, It is the second most common type of cancer and the most common one in women with about 22 thousand new cases in 2020.
- Trial name
- NCT05637671
- Testing
- oxybutynin ER, Paroxetine CR
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Cairo University
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life…
- Trial name
- RELIEF (NCT07490431)
- Testing
- No intervention
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Anxiety Disorder, Breast Cancer
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
- Trial name
- NCT00022074
- Testing
- gabapentin, quality-of-life assessment
- Where
- 18 sites in United States
- Sponsor
- Gary Morrow
Hot Flashes
A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms).
- Trial name
- GRACE (NCT07455812)
- Testing
- Fezolinetant
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Europe Ltd.
Hot Flashes, Menopause
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
Hot flashes can be a disturbing symptom of menopause. Prescription medications are commonly used for symptom relief. Several non-prescription therapies are under investigation.
- Trial name
- NCT00599456
- Testing
- Omega 3 fatty acid vitamins
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Christiana Care Health Services
Vasomotor Symptoms
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with…
- Trial name
- NCT00421031
- Testing
- DVS-233 SR
- Where
- 41 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Endothelial Dysfunction, Obesity
Leptin Infusion and Endothelial Vasomotor Response
Adipose tissue is an active endocrine organ producing several hormones with circulatory and metabolic effects. In 1994, the hormone leptin was discovered.
- Conditions
- Endothelial Dysfunction, Obesity, Vasodilation, Venous Occlusion Plethysmography
- Trial name
- LIVARM (NCT04374500)
- Testing
- Leptin infusion plus vasodilators in healthy men, Leptin infusion in healthy men, Vasodilators in CAD patients
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Stefan Soderberg
PMS, Hot Flashes
A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2A are more likely to cause hypothermia.
- Trial name
- RDC (NCT02100540)
- Testing
- II RDC 0.3mg capsule, III RDC 0.6mg capsule
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Vulvovaginal Atrophy, Vasomotor Symptoms
Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
Randomized, Open-label 2-arm, parallel group study in approximately 20 healthy postmenopausal women to assess the safety of DARE-HRT1 Intravaginal Rings in two different dose strengths and the PK of progesterone and estradiol…
- Trial name
- DARE-HRT1 (NCT05367973)
- Testing
- IVR Dose 1, IVR Dose 2
- Where
- 2 sites in Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.
Vulvovaginal Atrophy, Vasomotor Symptoms
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
- Trial name
- NCT05418426
- Testing
- IVR Dose 1, IVR Dose 2, Oral Reference
- Where
- 2 sites in Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Vasomotor Symptoms
Mindfulness-Based Stress Reduction for Hot Flashes
This is a study to determine if participation in a mindfulness-based stress reduction program is feasible for women experiencing five or more hot flashes/day, and whether it affects either the frequency and/or intensity of their…
- Trial name
- NCT01052454
- Testing
- Mindfulness-based stress reduction
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Menopause, Atherosclerosis
Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life
Although the impact of postmenopausal hormone therapy (HT) on cardiovascular disease risk has been studied in several large randomized trials, little is known about the acute cardiovascular consequences of HT discontinuation.
- Conditions
- Menopause, Atherosclerosis, Cardiovascular Diseases, Estrogen Replacement Therapy
- Trial name
- NCT04050592
- Testing
- Estradiol
- Where
- Finland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Hanna Savolainen-Peltonen
Menopause, Pharmacists
MOving Forward With MENopause Treatment Through Pharmacists' Expanded Roles in Hormone Health
The MOMENT project centres pharmacists as key partners for people assigned female at birth (AFAB) in improving menopause care. Menopause is a major life event, which half of our population will experience.
- Trial name
- MOMENT (NCT07618039)
- Testing
- Pharmacist-led menopause care
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Postmenopause, Hot Flashes
Comparison of Fluoxetine Versus Citalopram Therapy to Control Postmenopausal Vasomotor Syndrome
This study determined the efficacy of non-hormonal therapy with citalopram compared to fluoxetine, for the treatment of menopausal symptoms in Mexican women with vasomotor syndrome (VMS) and urogenital syndrome.
- Trial name
- NCT05346445
- Testing
- Fluoxetine 20 MG, Citalopram 20mg
- Where
- Mexico
- Volunteers
- 91 people
- Sponsor
- Hospital Regional 1o de Octubre
Menopause, Vasomotor System
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS)…
- Trial name
- NCT00369434
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR)
- Where
- 34 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer